Abstract:Background: The combination of the unique properties of cancer cells makes it possible to find specific ligands that interact directly with the tumor, and to conduct targeted tumor therapy. Phage display is one of the most common methods for searching for specific ligands. Bacteriophages display peptides, and the peptides themselves can be used as targeting molecules for the delivery of diagnostic and therapeutic agents. Phage display can be performed both in vitro and in vivo. Moreover, it is possible to carry out the phage display on cells pre-enriched for a certain tumor marker, for example, CD44 and CD133. Methods: For this work we used several methods, such as phage display, sequencing, cell sorting, immunocytochemistry, phage titration. Results: We performed phage display using different screening systems (in vitro and in vivo), different phage libraries (Ph.D-7, Ph.D-12, Ph.D-C7C) on CD44+/CD133+ and without enrichment U-87 MG cells. The binding efficiency of bacteriophages displayed tumor-targeting peptides on U-87 MG cells was compared in vitro. We also conducted a comparative analysis in vivo of the specificity of the accumulation of selected bacteriophages in the tumor and in the control organs (liver, brain, kidney and lungs). Conclusions: The screening in vivo of linear phage peptide libraries for glioblastoma was the most effective strategy for obtaining tumor-targeting peptides providing targeted delivery of diagnostic and therapeutic agents to glioblastoma.

In Vivo Selection of Phage Sequences and Characterization of Peptide-Specific Binding to Breast Cancer Cells

Selectively Suppressing Tumor Angiogenesis for Targeted Breast Cancer Therapy by Genetically Engineered Phage.

Guiding nanomaterials to tumors for breast cancer precision medicine: from tumor-targeting small-molecule discovery to targeted nanodrug delivery.

Cancer Therapy: Selectively Suppressing Tumor Angiogenesis for Targeted Breast Cancer Therapy by Genetically Engineered Phage (adv. Mater. 29/2020)

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer.

Selection and Characterization of a Peptide Specifically Targeting to Gastric Cancer Cell Line SGC-7901 Using Phage Display

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells

Selection of a Specific Binding Peptide Targeting to Blood Vessel of Human Gastric Cancer in Vivo and Modeling of Its Three Dimensional Structure

Identifying Peptides That Specifically Bind to MDA-MB-468 Breast Cancer Cells*

Selection of Lung Cancer-Specific Landscape Phage for Targeted Drug Delivery.

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging.

Screening of micromolecule polypeptide specific for bladder carcinoma cell T24

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Screening Tumor-Targeting Bacteriophage Particles by Pre-Clearing Phage Display

Generation of peptides using phage display technology for cancer diagnosis and molecular imaging

Detection of breast cancer-related antigens through cDNA phage-displayed protein microarray.